ALK-Abelló appoints EVP and head of North America operations

Danish allergy immunotherapy specialist ALK-Abello (ALKB: DC) has appointed Edward Jordan as new executive vice president (EVP) and head of commercial operations in North America, effective January 5, 2026.

Mr Jordan succeeds Søren Niegel who has  temporarily assumed the position following the decision, effective 1October 1, 2025, to elevate ALK’s two key commercial regions, Europe and North America. into the executive Leadership Team (ELT) to further strengthen the execution of ALK’s Allergy+ strategy.

An American citizen, Mr Jordon  brings more than 30 years of biopharmaceutical  experience, including roles at Schering-Plough now part of  Merck & Co (NYSE: MRK), Teva Pharmaceuticals (NSE:TEVA), and  DBV Technologies, deep expertise in allergy and immunology, comprising work on  Claritin, Clarinex, and Viaskin, as well as knowledge of the emerging food allergy  market. With a strong track record in US commercial strategy, product launches, and  market development, Edward Jordan has built therapeutic markets, established  European and Scandinavian companies in the USA, and advanced therapies that  improve patient outcomes.